ADVERTISEMENT
Opinion: Emergency Use Authorizations Are a Threat to Science<strong>&nbsp;</strong>
Opinion: Emergency Use Authorizations Are a Threat to Science 
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
Opinion: Emergency Use Authorizations Are a Threat to Science 
Opinion: Emergency Use Authorizations Are a Threat to Science 

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

regulation, disease & medicine

A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020 | 9 min read
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Ebola Vaccine Approved for Use in Europe
Jef Akst | Nov 11, 2019 | 1 min read
Merck’s Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.
DEA Again Promises to Improve Access to Marijuana for Research
Ashley Yeager | Aug 26, 2019 | 3 min read
After years of stalling, the agency says it plans to provide notice on pending applications from growers—but only after it establishes new regulations for suppliers.
cryopreservation facility
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019 | 6 min read
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
First New Tuberculosis Drug Approved in 50 Years
Jef Akst | Aug 15, 2019 | 2 min read
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
Survey of Stem Cell Clinics Reveals Cause for Concern
Jef Akst | Aug 1, 2019 | 4 min read
Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.
Couple With Cancer Wins $2 Billion in Case Against Monsanto
Catherine Offord | May 14, 2019 | 2 min read
In determining that the illnesses came about from exposure to glyphosate in Roundup, a California jury delivers the biggest loss so far to the herbicide manufacturer in lawsuits about the product.
Sunscreen Ingredients Absorbed into Blood: Study
Catherine Offord | May 7, 2019 | 2 min read
FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
april 2019 editorial the scientist
Miracle Elixirs
Bob Grant | Apr 1, 2019 | 3 min read
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
WHO Panel Calls For a Registry of Gene-Editing Research in Humans
Catherine Offord | Mar 20, 2019 | 2 min read
The advisors’ recommendations follow news of ethically dubious gene-editing work carried out by He Jiankui late last year.
cans of food, seen from the top
A Landmark Study On BPA Leaves Scientists at Odds
Shawna Williams | Oct 26, 2018 | 6 min read
Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.
Hundreds of Supplements Spiked with Pharmaceuticals
Ashley P. Taylor | Oct 14, 2018 | 2 min read
FDA does little about it, study finds.
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Catherine Offord | Jul 17, 2018 | 2 min read
Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018 | 2 min read
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
tamiflu
Updated Review: Tamiflu Is a Bust
Kerry Grens | Apr 10, 2014 | 2 min read
After finally getting their hands on full clinical study reports, independent reviewers say the antiviral drug is ineffective.
ADVERTISEMENT